CAR T-Cell Therapy

Tara Graff, DO, details the role of CAR T-cell therapy in the relapsed/refractory diffuse large B-cell lymphoma treatment paradigm.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

Jae Park, MD, discusses recent developments for obe-cel and brexu-cel in acute lymphoblastic leukemia.

Glofitamab combined with CAR T-cell therapy is associated with improved outcomes in relapsed/refractory B-cell lymphoma.

Obe-cel is associated with durable survival outcomes in relapsed/refractory B-ALL, regardless of BOR of CR or CRi.

Rapcabtagene autoleucel exhibited promising response and safety data in relapsed or refractory B-cell acute lymphoblastic leukemia.

Updated data from TRANSCEND FL showed durable efficacy outcomes with liso-cel in relapsed/refractory follicular lymphoma.

Retrospective data showed longer durations of bridging therapy with a BTK inhibitor improved CAR T-cell therapy response in relapsed/refractory DLBCL.

Data from China showed relma-cel yielded durable responses in patients with relapsed/refractory mantle cell lymphoma.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

OncLive heard from experts across oncology specialties about the biggest updates from the 2026 Transplantation and Cellular Therapy Meetings.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in January 2025 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in acute lymphoblastic leukemia, breast cancer, urothelial cancer, ovarian cancer, and follicular lymphoma.

The FDA granted priority review to Dato-DXd in triple-negative breast cancer, accepted an NDA for zanzalintinib plus atezolizumab in mCRC, and more.

CARTITUDE-4 data show heterogeneous outcomes with cilta-cel after progression on bridging therapy in relapsed/refractory multiple myeloma.

The FDA updated axi-cel labeling to remove the limitation of use for patients with relapsed or refractory primary central nervous system lymphoma.

Prophylactic dexamethasone did not reduce the risk of developing DNT, nor the severity of DNT presentation, in cilta cel–treated myeloma with high ALC.

Nogapendekin alfa inbakicept plus PD-L1 t-haNK and bevacizumab produced encouraging overall survival data in recurrent glioblastoma.

Sofi-cel has received FDA breakthrough therapy designation for heavily pretreated patients with relapsed/refractory T-ALL and T-LBL.

Treatment with an allogeneic CD19-directed CAR natural killer–cell therapy led to an ongoing complete response at 15 months in Waldenstrom lymphoma.

The FDA will increase its flexibility on CMC requirements for cell and gene therapies to speed their development and better support BLA planning.

The first-in-class, CXCR4hi regulatory T-cell therapy CK0804 received orphan drug designation for patients with myelofibrosis.

Here is your Q1 2026 preview spotlighting 5 FDA decisions to watch, including upcoming PDUFAs for tabelecleucel, pembrolizumab, and more.

Obe-cel produced responses and low rates of high-grade CRS and ICANS in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.